Drugs / Lactobacillus casei
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06793514 | Feb → May 2025 overdue | dry eye syndrome | Mohsen Pourazizi | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06560879 | Feb → Dec 2025 overdue | digestive system disorder, precursor lymphoblastic lymphoma/leukemia | National Institute of Pediatrics, Mexico | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03033199 | Jan 2017 → Feb 2018 | autoimmune thrombocytopenia | Shandong University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01534754 Comparator | Jan 2009 → Oct 2011 | colonic disorder | Hospital Cristo Re | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus casei | “The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium...” NCT06793514 ↗3“probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one...” NCT03033199 ↗ |
| Route | Oral | “orally intake either probiotic supplements” NCT03033199 ↗ |